A recent study reported that ESS2 regulated prostate cancer proliferation primarily through the NF-κB/CHD1 pathway and that ESS2 knockdown lowered histone H3K36 trimethylation levels on the target gene promoters in castration-resistant prostate cancer (CRPC) cells [59]. This evidence concerns the gene CHD1 and prostate carcinoma.